A study of pegylated alfa interferon, sunitinib and Tarceva [erlotinib] in patients with metastatic renal cell carcinoma

Trial Profile

A study of pegylated alfa interferon, sunitinib and Tarceva [erlotinib] in patients with metastatic renal cell carcinoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Erlotinib (Primary) ; Peginterferon alfa (Primary) ; Sunitinib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Aug 2008 Actual patient number added (10) as reported by ClinicalTrials.gov.
    • 24 Aug 2008 Planned end date added (1 Jul 2008) as reported by ClinicalTrials.gov.
    • 24 Aug 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top